All News
Outcomes of COVID-19 in Patients with Rheumatoid Arthritis
Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19 outcomes remains uncertain.
Read ArticleLinks:
Links:
Links:
Richard Conway RichardPAConway ( View Tweet)
Links:
Links:
RheumNow Podcast – ACR Convergence Begins (11.5.2021)
Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
Read ArticleProlonging the Controversy of Hydroxychloroquine
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19.
Read ArticleACR21 Previews from Creaky Joints
CreakyJoints will present 11 posters and two oral presentations at ACR 2021. COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which were linked to medication interruptions and associated flares suggesting during the pandemic, patients often felt unsupported by all levels of the healthcare system.
Read Article